Business Context and Reporting Period
Company: Bionexus Gene Lab Corp (BGLC)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: BGLC operates through two primary Malaysian subsidiaries: Chemrex Corporation Sdn. Bhd., which distributes industrial chemical raw materials (primarily fiber-reinforced polymers), and MRNA Scientific Sdn. Bhd., which provides blood-based genomic screening services. In November 2025, the Company expanded its strategic focus by entering into a Share Subscription and Shareholders' Agreement with Fidelion Diagnostics Pte. Ltd. and securing an exclusive license for the VitaGuard™ Minimal Residual Disease (MRD) platform in Southeast Asia.
Key Financial Metrics
| Metric | 2025 (USD) | 2024 (USD) |
|---|---|---|
| Total Revenue | $7,424,911 | $9,510,646 |
| Gross Profit | $1,085,217 | $1,289,521 |
| Net Loss | $(2,984,607) | $(1,598,342) |
| Operating Cash Flow | $(1,838,382) | $(2,093,260) |
| Working Capital | $4,927,781 | $5,479,146 |
| Cash and Equivalents | $2,486,383 | $2,886,966 |
| Accumulated Deficit | $(6,427,227) | $(3,442,620) |
Segment Performance: Chemrex generated $7.41M in revenue (99.7% of total), while MRNA Scientific generated $19.1K (0.3%). Gross margins were 14.6% for Chemrex and 51.1% for MRNA Scientific.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 21.9% year-over-year, driven primarily by a 22% drop in Chemrex sales volume due to management changes and customer relationship impacts.
- Increased Net Loss: Net loss widened by 87% to $2.98M. This was caused by lower "Other Income" (specifically a $1.54M reduction in the reversal of expected credit losses) and increased share-based compensation ($794.8K vs $141K in 2024).
- Capital Structure: The Company executed a 1-for-10 reverse stock split effective April 7, 2025, to regain Nasdaq compliance. Outstanding shares increased to 2,417,314 by year-end due to strategic issuances.
- Strategic Transactions: The Company issued 392,329 shares to Fidelion Diagnostics and 175,000 shares to ARC Group International Ltd. as consideration for strategic agreements and financing commitments.
Guidance, Outlook, Risks, and Contingencies
Outlook and Strategic Initiatives
- VitaGuard™ Deployment: The Company announced the formal commencement of the deployment phase for the VitaGuard™ MRD platform in January 2026.
- Financing: An At-The-Market (ATM) offering program with Maxim Group LLC was activated, with $267,311 raised as of the filing date. An Equity Purchase Agreement with ARC Group International Ltd. provides access to up to $500M in financing over 36 months.
- Ethereum Strategy: The Company adopted an Ethereum-focused treasury strategy in March 2025.
Risks and Contingencies
- Going Concern: The independent auditor has raised substantial doubt about the Company's ability to continue as a going concern due to continuous losses and negative operating cash flows. Management's plans rely on external financing and improved profitability.
- Internal Control Weaknesses: A material weakness in internal controls was identified at the Chemrex subsidiary regarding unauthorized transactions and lack of board oversight. Remediation is ongoing, including the resignation of four Chemrex officers/directors in December 2025.
- Related Party Transactions: Historical transactions with entities affiliated with former directors (e.g., Honkuk Material Sdn. Bhd.) were identified without prior board approval. These are under review for ratification or potential recovery of funds.
- Regulatory Compliance: The Company previously faced Nasdaq delisting risks due to bid price deficiencies, which were remedied via the reverse stock split.
Investor Verification Checklist
- Going Concern Status: Verify the Company's ability to secure the external financing required to sustain operations beyond the next 12 months.
- Internal Control Remediation: Monitor the progress of the Audit Committee's investigation into Chemrex governance lapses and the ratification of unauthorized related-party transactions.
- Revenue Sustainability: Assess whether Chemrex can recover sales volume following the management transition and if the VitaGuard™ platform will generate meaningful revenue in 2026.
- Dilution Risk: Review the impact of the ATM program and the ARC Group commitment shares on existing shareholder equity.
- License Obligations: Confirm the Company's ability to meet the $2M license fee payment schedule and $500K reagent purchase commitment to Fidelion Diagnostics.